SynthesisBMC neurology2026
Efficacy and Safety of tirofiban in acute ischemic stroke patients with early neurological deterioration: a meta-analysis.
Synthesis in BMC neurology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundPatients with acute ischemic stroke (AIS) who experience early neurological deterioration (END) often face significant neurological disability. Given the limited efficacy of current oral antiplatelet regimens in this period, tirofiban has emerged as a potential therapeutic candidate for investigation. However, there is a lack of meta-analyses specifically assessing this effect and safety in this patient population.
methodsA meta-analysis analyzed PubMed, EMBASE, Web of Science, and Cochrane Library up to July 2025. Included studies compared tirofiban with control treatment in adult AIS patients with END. Outcomes included 90-day favorable functional outcome (mRS ≤ 2), intracerebral hemorrhage (ICH), peripheral bleeding and mortality.
resultsSeven studies (4 RCTs, 3 cohorts; 805 patients) were included. Tirofiban significantly improved 90-day functional outcomes (OR = 2.66, 95% CI 1.88–3.75; P < 0.00001), with consistent benefits in subgroups receiving or not receiving rt-PA (OR = 2.28 and 2.89, respectively). No significant increases were observed in ICH (OR = 1.46, 95% CI 0.61–3.47; P = 0.39), peripheral bleeding (OR = 1.77, 95% CI 0.94–3.32; P = 0.08), or mortality (OR = 1.02, 95% CI 0.40–2.62; P = 0.96). Heterogeneity was low, and methodological quality was high.
conclusionsOur findings suggest that tirofiban may improve 90-day functional outcomes in AIS patients with END, irrespective of rt-PA use. There was no statistically significant increase in the risk of intracranial hemorrhage, peripheral bleeding, or mortality.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.